Category

Lundbeckfonden Emerge
Andreas Jurgeit is to join Lundbeckfonden Emerge, the early stage investment unit of the Lundbeck Foundation, as a partner on 1 January 2019. Andreas has been active in various operational and financing roles over the last decade. He was first exposed to biotech as a scientist collaborating with 3V Biosciences during his PhD and later...
Copenhagen, Denmark – September 27th, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small...
SAN DIEGO and COPENHAGEN, Denmark, July 23, 2018 /PRNewswire/ — Dermtreat, a clinical-stage biopharmaceutical company focused on mucosal diseases, today announced treatment of the first patient in a Phase 2b clinical trial of Rivelin® Clobetasol patch (Rivelin®-CLO) for oral lichen planus (OLP). Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol...
Copenhagen, Denmark – August 29th, 2017: Danish-based Dermtreat today announced the GMP (Good Manufacturing Practices) approval for the production of its novel Rivelin® patch – a breakthrough therapy in treating mucosal diseases. Dermtreat has developed the Rivelin® patch – a breakthrough therapy for the treatment of mucosal diseases. Rivelin® is designed to deliver a pharmaceutical...
Copenhagen, Denmark – May 8, 2017: Danish-based Dermtreat today announced the successful closure of a USD 17.7 mill. Series A financing led by the US-based leading venture capital firm, Sofinnova, with the leading Nordic venture capital firms Novo Seeds and Lundbeckfonden Emerge in the syndicate. Existing shareholders are also participating. Dermtreat has developed the Rivelin®...
NMD Pharma develops new treatments, improving the signaling of the nerves to the muscles, to patients suffering from orphan motor neuron diseases including Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). The company has identified a novel disease target and developed new small molecule drug-like compounds effectively increasing neuromuscular transmission. In models...
 IO Biotech today announced the successful completion of a ?11 million Series A financing round. Participants were new investor Lundbeckfonden as well as existing investor Novo A/S.
Lundbeck Foundation is investing a further DKK 15 million in Aarhus-based Insusense Therapeutics, a biotech company which develops new drugs for the treatment of type 2 diabetes and obesity.
Lundbeck Foundation has decided to invest DKK 300 million in Danish biotech companies over the next four years. The funds will be invested by Lundbeckfond Emerge with the aim of generating a portfolio of five active companies over the course of a couple of years.

News

Danish scientists shed new light on overwhelming need to sleep
19. February 2019
Largest study yet links so-called cat-poo parasite to schizophrenia
2. February 2019
Scientists identify links between psychiatric disorders and events during the foetal stage
28. January 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge